Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.
Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
J Diabetes Investig. 2021 Dec;12(12):2162-2171. doi: 10.1111/jdi.13598. Epub 2021 Jun 16.
AIMS/INTRODUCTION: Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting.
A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated.
Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs.
All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
目的/引言:已注意到胰高血糖素样肽-1 受体激动剂(GLP-1RAs)在降低血糖机制方面存在差异。阐明这些差异可以促进为 2 型糖尿病患者选择最佳药物,并需要在临床环境中进行研究。
进行了一项单臂、前瞻性、观察性研究,以评估各种 GLP-1RA 对餐后血糖波动、胰岛素和胰高血糖素分泌以及胃排空率的影响。在 GLP-1RA 开始前、2 周和 12 周后,参与者接受了耐量试验。还研究了餐后葡萄糖依赖性胰岛素释放多肽(GIP)和载脂蛋白 B48 的分泌情况。
18 例 2 型糖尿病患者接受了三种 GLP-1RA 中的一种,即利西那肽(lixisenatide),n=7;利拉鲁肽(liraglutide),n=6;或度拉糖肽(dulaglutide),n=5。虽然所有 GLP-1RA 的 12 周治疗均显著降低了 HbA1c,但只有利西那肽和利拉鲁肽而非度拉糖肽显著降低了体重。所有 GLP-1RA 均改善了餐后血糖升高。利西那肽抑制了餐后胰岛素水平,而利拉鲁肽增强了胰岛素水平。利西那肽抑制了餐后胰高血糖素水平。利西那肽显著延迟了胃排空,而利拉鲁肽和度拉糖肽对胃排空的影响有限。GIP 分泌被利西那肽和利拉鲁肽抑制。所有 GLP-1RA 均抑制了载脂蛋白 B48 的分泌。
在日本 2 型糖尿病患者的为期 12 周的前瞻性观察性研究中,发现所有 GLP-1RA 均能改善 HbA1c。然而,观察到降低血糖作用和体重减轻的机制存在差异。